Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)
Information source: Tottori University Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Stable Heart Failure
Intervention: spironolactone + furosemide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Tottori University Hospital
Summary
The purpose of this study is to evaluate the effects of spironolactone and furosemide on
insulin resistance in patients with chronic heart failure.
Clinical Details
Official title: Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study
Primary outcome: insulin resistance
Detailed description:
Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism.
Therefore, the purpose of this study is to evaluate the effects of spironolactone and
furosemide on insulin resistance in patients with chronic heart failure.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- chronic stable heart failure
Exclusion Criteria:
- renal dysfunction or under treatment with antidiabetic agents
Locations and Contacts
Additional Information
Starting date: January 2004
Ending date: December 2005
Last updated: April 21, 2008
|
